Peptides from Amaranth controlled the NF-κB pathway activation on epithelial cells and suppressed intestinal inflammation by Smaldini, Paola et al.
Peptides from Amar,anth controlled the NF-KB pathway activation on epithelial 
cells and suppressed intestinal inflammation 
I I F p 
Paola L Smaldini, Micaela Quereda, Gaston Rizzo, Maria Lucia Orsini Delgado, Julian Moronta, Cristina Afi6n, Guillermo Docena 
1-lnstituto de Estudios fnmunologicos y Fisiopatologicos-lJFP, Facultad de Ciencias Exactas, UNLP La Plata, ARGENTINA 
2-Centro de lnvestigacion y desarrolfo en Tecnologfa de Alimentos {CIDCA), CONIC ET CCT La Plata y UNLP, Argentina 
Introduction & Aim MaterJals & Methods 
In vitro assays: immunomodulation of Caco-luciferase cell line 
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Biological, nutritional and hea lth benefits of amaranth have been highlighted in the last years . Proteins of 
amaranth exert anti-hypertensive, anti -oxidant, anti-thrombotic and anti-·proliferative effects .. The aim of this study 
was to analyze the anti-inflamm atory effect of peptides from amaranth on NF-kB-intracellular pathway activation 
in intestinal epithelial ce lls, and in experimental intestinal inflammation, such as colitis and food allergy. 
Mouse model: a cholera toxin-driven Th2 specific immune response was proimoted in Balb/c mice by gavage, and 
hyperse nsitivity reacti ons were evidenced im1mediately after the oral challenge with CMP. And a colitis mouse model, 
Balb/c were intrarectally administrated with TNBS or ethanol (EtOH) at day 0, mice were sacrificed at day 7 
Previously, we characterized peptides with anti-inflammatory properties in vitro . 
Results 
In vivo parameters: clinical score, skin test were analyzed, weight 
In vitro parameters: serum specific isotypes , cytokines, mucosal Tregs and cytokines, were assessed. 
Therapeutic strategies: synthetic peptide of amaranth were orally administrated. 
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Table 1. Clinical score assigned to symptoms 
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Figure 1. Sensitization and immunomodulation protocol 
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Figure 3. Cutaneous tests after immunomodulation. 
sensitized animals showed cutaneous inflammation (b lue} , 
whereas in treated animals vascular leal<a,ge was 
controlled . 
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Figure 4. Serum1 specific isotypes. We found decreased of 
CMP-specific lgE and lgG1 on t reated mice. 
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Figure 5. Cytokines. Cytokines in the supernatants of spleen cells stimulated 
with CMP or medium for 72 h. Treated mice showed lower production of Th2 
cytokines. 
Figure 6. Local cytokine and transcription factors expression on gut: 
i.R (EtOH/TNIBS-EtOH) 130 
110 
Treated mice expressed less amounts of Ccl20, Gata-3 and NF-KB, with 
increase in TGF-13 and FoxP3 . 
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Figure 8. Protocol for induction of colitis. 
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Figure 9. Body weight. Peptide 2 treatment 
attenuates weight loss in mice with TNBS-induced 
colitis 
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Figure 10. Disease activity index. 
IP2-treated mice showed lower 
activity. 
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Figure 11. H&E and h istologic activity i;ndex. IP2-treated mice showed a 
lower recruitment of inflammatory cells. Magnification: 400X, scale bar: 1 OOµm 
Figure 1.2. Myeloperoxidase activity on gut. 
Figure '13. Cytolk in e pro du cti on 
on colon tissue. Mice treated with 
the peptide produced less amount 
of pro-inflammatory cytokines 
Conclusions 
v"'The peptide P2 from Amaranth controlled the Th2-mediated allergic response, decreasing clinical score and cutaneous test in vivo, 
serum lgE levels and Th2 profile cytokines in vitro. 
v"'The peptide P2 from Amaranth ameliorates weight loss, clinical score and mucosal inflammation in a TNBS-induced mouse colitis 
model . 
These findinas led us to orooose that this oeotide miaht be included in the composition of a functional food 
